Developments ADC announces updated data from trial of ZYNLONTA with glofitamab in r/r DLBCL ADC Therapeutics (NYSE: ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in... December 3, 2025